These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 18245967

  • 21. Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens.
    Comstock TL, Holland EJ.
    Expert Opin Pharmacother; 2010 Apr; 11(5):843-52. PubMed ID: 20210687
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis.
    Torkildsen GL, Cockrum P, Meier E, Hammonds WM, Silverstein B, Silverstein S.
    Curr Med Res Opin; 2011 Jan; 27(1):171-8. PubMed ID: 21138337
    [Abstract] [Full Text] [Related]

  • 23. Pharmacological validation of a feline model of steroid-induced ocular hypertension.
    Bhattacherjee P, Paterson CA, Spellman JM, Graff G, Yanni JM.
    Arch Ophthalmol; 1999 Mar; 117(3):361-4. PubMed ID: 10088814
    [Abstract] [Full Text] [Related]

  • 24. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M, Grigera DE, Barbosa WL, Jordao M, Susanna R.
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [Abstract] [Full Text] [Related]

  • 25. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1.
    Stewart R, Horwitz B, Howes J, Novack GD, Hart K.
    J Cataract Refract Surg; 1998 Nov; 24(11):1480-9. PubMed ID: 9818338
    [Abstract] [Full Text] [Related]

  • 26. Intraocular pressure response to loteprednol etabonate in known steroid responders.
    Bartlett JD, Horwitz B, Laibovitz R, Howes JF.
    J Ocul Pharmacol; 1993 Nov; 9(2):157-65. PubMed ID: 8345288
    [Abstract] [Full Text] [Related]

  • 27. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis.
    Asbell P, Howes J.
    CLAO J; 1997 Jan; 23(1):31-6. PubMed ID: 9001768
    [Abstract] [Full Text] [Related]

  • 28. Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis.
    Comstock TL, DeCory HH.
    Ocul Immunol Inflamm; 2017 Apr; 25(2):267-274. PubMed ID: 26788833
    [Abstract] [Full Text] [Related]

  • 29. Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery.
    Russo S, Papa V, Di Bella A, Favero A, Radulescu C, Gafencu O, Carstocea B, Milazzo G.
    Eye (Lond); 2007 Jan; 21(1):58-64. PubMed ID: 16273088
    [Abstract] [Full Text] [Related]

  • 30. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group.
    Am J Ophthalmol; 1999 May; 127(5):537-44. PubMed ID: 10334346
    [Abstract] [Full Text] [Related]

  • 31. Steroid-induced intraocular pressure elevation or glaucoma after penetrating keratoplasty in patients with keratoconus or Fuchs dystrophy.
    Erdurmus M, Cohen EJ, Yildiz EH, Hammersmith KM, Laibson PR, Varssano D, Rapuano CJ.
    Cornea; 2009 Aug; 28(7):759-64. PubMed ID: 19574912
    [Abstract] [Full Text] [Related]

  • 32. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE, Allaire C, Bateman KM, Gearinger LS, Morris TW, Comstock TL.
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [Abstract] [Full Text] [Related]

  • 33. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I.
    Friedlaender MH, Howes J.
    Am J Ophthalmol; 1997 Apr; 123(4):455-64. PubMed ID: 9124242
    [Abstract] [Full Text] [Related]

  • 34. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
    Sheppard JD, Donnenfeld ED, Holland EJ, Slonim CB, Solomon R, Solomon KD, McDonald MB, Perry HD, Lane SS, Pflugfelder SC, Samudre SS.
    Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
    [Abstract] [Full Text] [Related]

  • 35. Loteprednol etabonate suspension 0.2% administered QID compared with olopatadine solution 0.1% administered BID in the treatment of seasonal allergic conjunctivitis: a multicenter, randomized, investigator-masked, parallel group study in Chinese patients.
    Gong L, Sun X, Qu J, Wang L, Zhang M, Zhang H, Wang L, Gu Y, Elion-Mboussa A, Roy L, Zhu B.
    Clin Ther; 2012 Jun; 34(6):1259-1272.e1. PubMed ID: 22627057
    [Abstract] [Full Text] [Related]

  • 36. Effects of corneal nerve density on the response to treatment in dry eye disease.
    Kheirkhah A, Dohlman TH, Amparo F, Arnoldner MA, Jamali A, Hamrah P, Dana R.
    Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
    [Abstract] [Full Text] [Related]

  • 37. A comparison of intraocular pressure elevating activity of loteprednol etabonate and dexamethasone in rabbits.
    Bodor N, Bodor N, Wu WM.
    Curr Eye Res; 1992 Jun; 11(6):525-30. PubMed ID: 1505197
    [Abstract] [Full Text] [Related]

  • 38. Duration of IOP reduction with travoprost BAK-free solution.
    Gross RL, Peace JH, Smith SE, Walters TR, Dubiner HB, Weiss MJ, Ochsner KI.
    J Glaucoma; 2008 Jun; 17(3):217-22. PubMed ID: 18414108
    [Abstract] [Full Text] [Related]

  • 39. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation.
    Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR, Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group.
    Ophthalmology; 2007 Sep; 114(9):1653-62. PubMed ID: 17445902
    [Abstract] [Full Text] [Related]

  • 40. Topical and oral ketorolac administration increases the intraocular pressure-lowering effect of latanoprost.
    Costagliola C, Campa C, Perri P, Parmeggiani F, Romano MR, Incorvaia C.
    Curr Eye Res; 2008 May; 33(5):477-82. PubMed ID: 18568885
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.